May 20, 2025
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
Mar 05, 2025
SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
Feb 19, 2025
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
Jan 24, 2025
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
Dec 18, 2024
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Oct 16, 2024
Copper-67 SAR-bisPSMA updates
Oct 14, 2024
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer
Sep 12, 2024
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort
Aug 22, 2024
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
Mar 08, 2024
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
Jul 23, 2020
Clarity Pharmaceuticals opens SARTATE neuroblastoma clinical trial
Jul 21, 2020
Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets
Jun 03, 2020
Clarity Pharmaceuticals Announces that the US FDA Grants Rare Pediatric Disease Designation to 67Cu-SARTATE(TM) for the Treatment of Neuroblastoma
Apr 21, 2020
Clarity Pharmaceuticals Announces US FDA Grants 67Cu-SARTATE(TM) Orphan Drug Designation for Neuroblastoma
Mar 31, 2020
Clarity appoints Dr Gillies O'Bryan-Tear to Chair Newly Formed Global Clinical Development Group
Mar 20, 2020
Prof. Oliver Sartor Joins Clarity's Advisory Board